Conv. Plasma
Nigella Sativa

All antiandrogen studies
Meta analysis
study COVID-19 treatment researchAntiandrogenAntiandrogens (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ ICU admission 81% Improvement Relative Risk ICU admission (b) 86% Mortality -50% Mortality (b) -35% Antiandrogens  Goren et al.  LATE TREATMENT Is late treatment with antiandrogens beneficial for COVID-19? Prospective study of 77 patients in Brazil Lower ICU admission with antiandrogens (not stat. sig., p=0.082) Goren et al., J. the European Academy .., Sep 2020 Favors various Favors control

Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men

Goren et al., Journal of the European Academy of Dermatology and Venereology, doi:10.1111/jdv.16953, NCT04368897
Sep 2020  
  Source   PDF   All   Meta
7th treatment shown to reduce risk in September 2020
*, now known with p = 0.000000056 from 49 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Prospective study of 77 men hospitalized with COVID-19, 12 taking antiandrogens (9 dutasteride, 2 finasteride, 1 spironolactone), showing lower ICU admission with treatment (statistically significant with age-matched controls only when excluding the spironolactone patient). NCT04368897 (history).
risk of ICU admission, 81.0% lower, RR 0.19, p = 0.08, treatment 1 of 12 (8.3%), control 17 of 36 (47.2%), NNT 2.6, adjusted per study, age-matched controls.
risk of ICU admission, 86.0% lower, RR 0.14, p = 0.04, treatment 1 of 12 (8.3%), control 38 of 65 (58.5%), NNT 2.0, adjusted per study, all controls.
risk of death, 50.0% higher, RR 1.50, p = 1.00, treatment 1 of 12 (8.3%), control 2 of 36 (5.6%), age-matched controls.
risk of death, 35.4% higher, RR 1.35, p = 0.58, treatment 1 of 12 (8.3%), control 4 of 65 (6.2%), all controls.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Goren et al., 25 Sep 2020, prospective, Brazil, peer-reviewed, 15 authors, trial NCT04368897 (history).
This PaperAntiandrogensAll
Are SARS‐CoV‐2 IgA antibodies in paediatric patients with chilblain‐like lesions indicative of COVID‐19 asymptomatic or paucisymptomatic infection?
A Diociaiuti, S Giancristoforo, S Terreri, M Corbeddu, C Concato, M Ciofi Degli Atti, G Zambruno, R Carsetti, M El Hachem
Journal of the European Academy of Dermatology and Venereology, doi:10.1111/jdv.16934
was positive in eight cases, borderline in two, and negative in three, including the COVID-19 patient. Overall, serology for S1-specific IgA and IgG in the 30 patients shows that 16 (53.3%) were positive for IgA, whereas IgG was detectable in five (16.6%; Fig. 1f ). We have recently reported that high levels of IgG and IgA can be detected in adult patients with severe COVID-19, while IgA, and to a lower extent IgG, is increased in asymptomatic individuals. 6 As IgA is the most abundant antibody at mucosal sites, a strong local protection may prevent viral spread and damage to the respiratory tract, explaining the lack of symptoms. The ELISA used for the detection of anti-S1 IgG and IgA has been demonstrated to be specific and sensitive. 7, 8 Of note, antibodies against S1 are often neutralizing 9 and may prevent severe disease and further immune responses. 6 Our findings indicate that, similar to asymptomatic adults, paediatric patients would respond to SARS-CoV-2 producing more IgA than IgG. On the other hand, a single patient had detectable IgG against SARS-CoV-2 nucleoprotein. Anti-nucleoprotein IgG is present in the great majority of hospitalized adult patients, but only in one-third of paucisymptomatic individuals, suggesting that disease severity influences the specificity of the antibodies produced. 10 In conclusion, the detection of S1-specific IgA in paediatric patients with chilblain-like lesions strongly points to a previous, mostly asymptomatic SARS-CoV-2 infection with inflammatory sequelae.
Conflicts of interest None to be reported for all authors. A. Diociaiuti, 1,*, † S. Giancristoforo, 1, † S. Terreri, 2 M. Corbeddu, 1 C. Concato, 3 M. Ciofi Degli Atti, 4 G. Zambruno, 5 R. Carsetti, 6, † M. El Hachem 1, † Conflicts of interest None declared.
Andina, Noguera-Morel, Bascuas-Arribas, Chilblains in children in the setting of COVID-19 pandemic, Pediatr Dermatol
Beavis, Matushek, Abeleda, Evaluation of the EUROIM-MUN Anti-SARS-CoV-2 ELISA assay for detection of IgA and IgG antibodies, J Clin Virol
Carsetti, Zaffina, Mortari, Spectrum of innate and adaptive immune response to SARS CoV 2 infection across asymptomatic, mild and severe cases; a longitudinal cohort study, medRxiv, doi:10.1101/2020.06.22.20137141
Caturegli, Materi, Howard, Caturegli, Clinical validity of serum antibodies to SARS-CoV-2: a case-control study, Ann Intern Med
Cleach, Dousset, Assier, Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on PCR and serology testing, Br J Dermatol
El Hachem, Diociaiuti, Concato, A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric patients with chilblain-like lesions: lights and shadows on the relationship with COVID-19 infection, J Eur Acad Dermatol Venereol
Freeman, Mcmahon, Lipoff, Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries, J Am Acad Dermatol
Gebhard, Regitz-Zagrosek, Neuhauser, Morgan, Klein, Impact of sex and gender on COVID-19 outcomes in Europe, Biol Sex Differ
Ghazizadeh, Majd, Richter, Androgen regulates SARS-CoV-2 receptor levels and is associated with severe COVID-19 symptoms in men, bioRxiv, doi:10.1101/2020.05.12.091082
Grzelak, Temmam, Planchais, SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors, medRxiv, doi:10.1101/2020.04.21.20068858
Montopoli, Zumerle, Vettor, Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a populationbased study (N = 4532), Ann Oncol
Salgado, Handler, Schwartz, Shedding light on onychomadesis, Cutis
Seydoux, Homad, Maccamy, Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation, Immunity
Wadman, Sex hormones signal why virus hits men harder, Science
Wambier, Goren, Vaño-Galv An, Androgen sensitivity gateway to COVID-19 disease severity, Drug Dev Res
Wambier, Vaño-Galv An, Mccoy, Androgenetic alopecia present in the majority of hospitalized COVID-19 patients -the "Gabrin sign, J Am Acad Dermatol
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop